| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 02/01/2011 | CA2641952C Treatment of early stage idiopathic pulmonary fibrosis |
| 02/01/2011 | CA2551529C Amide derivative and medicine |
| 02/01/2011 | CA2505918C A liposome having bound albumin and peg |
| 02/01/2011 | CA2481560C Multiple acting anti-angiogenic and cytotoxic compounds and methods for using the same |
| 02/01/2011 | CA2481055C Combinations of quinolinone derivatives and 5-fu or cpt 11 |
| 02/01/2011 | CA2476298C Carbocyclic and oxacarbocyclic fumaric acid oligomers |
| 02/01/2011 | CA2454804C Probiotic lactobacillus salivarius strains |
| 02/01/2011 | CA2454120C Taxol enhancer compounds |
| 02/01/2011 | CA2453747C Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines and their use |
| 02/01/2011 | CA2453442C Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases |
| 02/01/2011 | CA2425172C Methods of decreasing or preventing pain using spicamycin derivatives |
| 02/01/2011 | CA2418656C Proline derivatives and use thereof as drugs |
| 02/01/2011 | CA2408685C Liquid pharmaceutical composition containing an erythropoietin derivate |
| 02/01/2011 | CA2406212C Substituted styryl benzylsulfones for treating proliferative disorders |
| 02/01/2011 | CA2403424C Flavone derivatives, preparation method and use as medicines |
| 02/01/2011 | CA2380550C C type lectin transmembrane antigen expressed in human prostate cancer and uses thereof |
| 02/01/2011 | CA2369560C Agent for prophylaxis and treatment of liver disease |
| 02/01/2011 | CA2315717C Inhibition of raf kinase using substituted heterocyclic ureas |
| 02/01/2011 | CA2315713C Inhibition of raf kinase using aryl and heteroaryl substituted heterocyclic ureas |
| 02/01/2011 | CA2288943C Ricin-like toxin variants for treatment of cancer, viral or parasitic infections |
| 02/01/2011 | CA2282779C Formulation comprising an antigen, an adjuvant and an amino acid for use in immunization. |
| 02/01/2011 | CA2273194C Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom |
| 02/01/2011 | CA2219978C Method for inhibiting neoplastic disease in mammals |
| 02/01/2011 | CA2188432C Melanoma antigens |
| 01/27/2011 | WO2011011692A2 Methods of treating and preventing/reducing the likelihood of mesial temporal lobe epilepsy (tle) |
| 01/27/2011 | WO2011011632A1 Methods and compositions for modulating membrane potential to influence cell behavior |
| 01/27/2011 | WO2011011617A1 Therapeutic compositions and methods |
| 01/27/2011 | WO2011011522A2 Potent small molecule inhibitors of autophagy, and methods of use thereof |
| 01/27/2011 | WO2011011453A2 Phenotyping tumor-infiltrating leukocytes |
| 01/27/2011 | WO2011011384A2 Synthesis of dendrimer conjugates |
| 01/27/2011 | WO2011011199A1 Combination therapies with ck2 modulators |
| 01/27/2011 | WO2011011186A2 Hdac inhibitors and therapeutic methods using the same |
| 01/27/2011 | WO2011011092A1 Methods and compositions to reduce oxidative stress |
| 01/27/2011 | WO2011011027A1 Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases |
| 01/27/2011 | WO2011010737A1 Guide nucleic acid for cleavage of micro-rna |
| 01/27/2011 | WO2011010715A1 Pr-set7 inhibitor |
| 01/27/2011 | WO2011010706A1 Fgf21 cis-element binding substance |
| 01/27/2011 | WO2011010583A1 Method for screening for oligonucleotide, and oligonucleotide library |
| 01/27/2011 | WO2011010083A1 Indolyl-pyridone derivatives |
| 01/27/2011 | WO2011010080A1 Inhibitor of inflammatory conditions |
| 01/27/2011 | WO2011010072A1 Selenoquinone-derived active organometallic complexes, methods for synthesizing same, and uses thereof |
| 01/27/2011 | WO2011009826A2 Novel chalcone derivatives with cytotoxic activity |
| 01/27/2011 | WO2011009714A2 Benzoquinolizinium salt derivatives as anticancer agents |
| 01/27/2011 | WO2011009695A1 New anti-angiogenic compounds |
| 01/27/2011 | WO2011009484A1 Arylpyrazoles and arylisoxazoles and their use as pkd modulators |
| 01/27/2011 | WO2011009226A1 Preparation method of dasatinib derivatives useful as antitumor agents and their intermediates |
| 01/27/2011 | WO2011009173A1 Cancer immunotherapy |
| 01/27/2011 | WO2010142956A3 Aroylthiourea and arylthiocarbonylurea derivatives |
| 01/27/2011 | WO2010135534A3 Compositions for the treatment of metastatic cancer and methods of use thereof |
| 01/27/2011 | WO2010134039A3 Mitochondrial activity inhibitors of cancer-initiating cells and use thereof |
| 01/27/2011 | WO2010133976A3 Substantially pure imatinib or a pharmaceutically acceptable salt thereof |
| 01/27/2011 | WO2010128087A3 Uses of immunoconjugates targeting cd138 |
| 01/27/2011 | WO2010118063A3 Pyruvate kinase m2 modulators, therapeutic compositions and related methods of use |
| 01/27/2011 | WO2010099445A3 Non-covalent inhibition of the 26s proteasome and uses thereof |
| 01/27/2011 | WO2010096434A3 Specific binding proteins and uses thereof |
| 01/27/2011 | US20110023137 Fusion protein comprising a caspase domain and a nuclear hormone receptor binding domain and methods and uses thereof |
| 01/27/2011 | US20110023135 Use of a new gene coding for a new member of the mcm2-8 family in pharmaceutical compositions |
| 01/27/2011 | US20110021766 Epimerized derivatives of k5 polysaccharide with a very high degree of sulfation |
| 01/27/2011 | US20110021637 Xanthohumol and tetrahydro-isoalpha acid based protein kinase modulation cancer treatment |
| 01/27/2011 | US20110021635 Rbm3 as a marker for breast cancer prognosis |
| 01/27/2011 | US20110021624 Alpha-Amino-N-Substituted Amides, Pharmaceutical Composition Containing Them and Uses Thereof |
| 01/27/2011 | US20110021620 Use of tea polyphenols in preparing medicaments for prevention or treatment of tumors |
| 01/27/2011 | US20110021617 Medicinal Acidic Cannabinoids |
| 01/27/2011 | US20110021609 MicroRNA Signatures Associated with Cytogenetics and Prognosis in Acute Myeloid Leukemia (AML) and Uses Thereof |
| 01/27/2011 | US20110021607 Methods and Compositions Relating to Carcinoma Stem Cells |
| 01/27/2011 | US20110021604 Methods and compositions for the specific inhibition of kras by asymmetric double-stranded rna |
| 01/27/2011 | US20110021603 TRPM-2 Antisense Therapy |
| 01/27/2011 | US20110021602 Graft polymers for enhanced intracellular delivery of antisense molecules |
| 01/27/2011 | US20110021601 Composition containing microrna-21 inhibitor for enhancing radiation sensitivity |
| 01/27/2011 | US20110021599 Methods and compositions for inhibiting or reducing hair loss, acne, rosacea, prostate cancer, and bph |
| 01/27/2011 | US20110021586 Phenyl-sulfamates as aromatase inhibitors |
| 01/27/2011 | US20110021582 Benzophenone thiazole derivatives useful for inhibiting formation of microtubule and method for producing the same |
| 01/27/2011 | US20110021574 Anti-cancer compounds, synthesis thereof, and methods of using same |
| 01/27/2011 | US20110021573 Antagonists of prostaglandin d2 receptors |
| 01/27/2011 | US20110021568 Tubulysin d analogues |
| 01/27/2011 | US20110021567 Preparation of lenalidomide |
| 01/27/2011 | US20110021559 Aminopyridines useful as inhibitors of protein kinases |
| 01/27/2011 | US20110021558 Thieno-pyridine derivatives as mek inhibitors |
| 01/27/2011 | US20110021554 Immune response modifier formulations and methods |
| 01/27/2011 | US20110021551 TREATMENT WITH OPIOID ANTAGONISTS AND mTOR INHIBITORS |
| 01/27/2011 | US20110021548 Inhibitors of malt1 proteolytic activity and uses thereof |
| 01/27/2011 | US20110021546 Gene Defects And Mutant ALK Kinase In Human Solid Tumors |
| 01/27/2011 | US20110021544 Hydrochloride salt of ((1s,2s,4r)-4--2-hydroxycyclopentyl)methyl sulfamate |
| 01/27/2011 | US20110021541 Inhibitors of human phosphatidyl-inositol 3-kinase delta |
| 01/27/2011 | US20110021540 Bis-(Sulfonylamino) Derivatives in Therapy 066 |
| 01/27/2011 | US20110021536 Crystalline Forms and Two Solvated Forms of 4-Amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one Lactic Acid Salts |
| 01/27/2011 | US20110021529 P53 activating compounds |
| 01/27/2011 | US20110021528 Novel hydroxamates as therapeutic agents |
| 01/27/2011 | US20110021525 P70S6 Kinase Modulators and Method of Use |
| 01/27/2011 | US20110021524 Compositions and methods for treating cancers |
| 01/27/2011 | US20110021523 Aryl sulfonamides |
| 01/27/2011 | US20110021522 Activators of executioner procaspases 3, 6 and 7 |
| 01/27/2011 | US20110021519 Tetrahydropteridines useful as inhibitors of protein kinases |
| 01/27/2011 | US20110021518 Pyrrolotriazine derivatives useful for treating cancer through inhibition of aurora kinase |
| 01/27/2011 | US20110021517 Antitumor combination comprising a morpholinyl anthracycline derivative and demethylating agents |
| 01/27/2011 | US20110021515 Dihyrofuropyrmindine compounds |
| 01/27/2011 | US20110021514 Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same |
| 01/27/2011 | US20110021511 Substituted 5h-pyrimido[5,4-b]indoles, method for the production thereof and use thereof for treating non-solid malignant tumors of the blood-producing system |
| 01/27/2011 | US20110021510 Methods of chemical synthesis and purification of diaminophenothiazinium compounds including methylthioninium chloride (mtc) |
| 01/27/2011 | US20110021508 Methods for Alzheimer's Disease Treatment and Cognitive Enhancement |